silybin has been researched along with Obesity in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Ababneh, Q; Alsaggar, M; Alzoubi, KH; Bdour, S; El-Elimat, T; Qinna, N | 1 |
| Chen, S; Jia, Y; Li, Z; Qi, L; Ren, L; Song, T; Wang, F | 1 |
| Avola, R; Barbagallo, I; Cinà, D; Currenti, W; D'Orazio, N; Galvano, F; Godos, J; Lembo, V; Li Volti, G; Morisco, F; Salomone, F | 1 |
| Gao, M; Hayashi, T; Ikeda, K; Ikejima, T; Li, D; Negishi, H; Sun, Y; Xu, F; Yang, J; Zhang, X | 1 |
| Alhado, M; Hernandez, AM; Menge, L; Price, RS; Sherman, B | 1 |
| Bouderba, S; Detaille, D; Koceïr, EA; Sanchez-Martin, C; Villanueva, GR | 1 |
| Galvano, F; Li Volti, G; Mangiameli, A; Salamone, F; Salomone, S; Siarkos, I; Sorrenti, V; Urso, V | 1 |
7 other study(ies) available for silybin and Obesity
| Article | Year |
|---|---|
Silibinin attenuates adipose tissue inflammation and reverses obesity and its complications in diet-induced obesity model in mice.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Body Weight; Diet, High-Fat; Disease Models, Animal; Gene Expression; Glucose; Hypertrophy; Liver; Male; Mice, Inbred C57BL; Obesity; Silybin | 2020 |
Proteomics study on the effect of silybin on cardiomyopathy in obese mice.
Topics: Adipose Tissue; Animals; Cardiomyopathies; Drug Evaluation, Preclinical; Lipid Metabolism; Male; Mice, Inbred C57BL; Obesity; Protective Agents; Proteome; Silybin | 2021 |
Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.
Topics: Adenylate Kinase; Animals; Diet, High-Fat; Gene Expression Regulation, Enzymologic; Hep G2 Cells; Humans; Mice; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease; Obesity; Silybin; Silymarin; Sirtuin 1 | 2017 |
Silibinin decreases hepatic glucose production through the activation of gut-brain-liver axis in diabetic rats.
Topics: Animals; Brain; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Supplements; Duodenum; Gastrointestinal Tract; Glucagon-Like Peptide-1 Receptor; Gluconeogenesis; Hyperglycemia; Hypoglycemic Agents; Liver; Liver Glycogen; Male; Neurons; Obesity; Rats, Sprague-Dawley; Rats, Zucker; Silybin; Solitary Nucleus; Specific Pathogen-Free Organisms; Vagotomy | 2018 |
Silibinin Differentially Decreases the Aggressive Cancer Phenotype in an In Vitro Model of Obesity and Prostate Cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; In Vitro Techniques; Male; Obesity; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Silybin; Tumor Microenvironment | 2020 |
Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Fatty Liver; Gerbillinae; Glutathione; Glutathione Peroxidase; Humans; Insulin; Lipids; Liver; Metabolic Syndrome; Obesity; Oxidative Stress; Silybin; Silymarin; Superoxide Dismutase | 2014 |
Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice.
Topics: Acetylcholine; Animals; Antioxidants; Aorta; Arginine; Diabetes Mellitus; Disease Models, Animal; Endothelium, Vascular; Insulin Resistance; Liver; Male; Mice; Mice, Obese; Nitroprusside; Obesity; Phenylephrine; Silybin; Silymarin; Vasoconstrictor Agents; Vasodilator Agents | 2011 |